This tool estimates the 5-year survival benefit of 1-year adjuvant anti-PD1 treatment after surgical R0 resection for clear-cell renal cell carcinoma (ccRCC). The calculation uses the average death-rate per year of any cause in The Netherlands (CBS), the cancer-specific survival based on the Leibovich score (2018 version) and the hazard ratio (HR) for adjuvant anti-PD1 therapy based on the KN-564 study.
Sex is only relevant for the death-of-any-cause estimation, not for adjustment of the KN-564 HR. The HR can be adjusted for WHO ECOG performance, based on the KN-564 findings: without ECOG input the model uses 0.62, for ECOG-1 0.82 and for ECOG-0 0.55. The 10y survival prediction is for consultation without adjuvant therapy only, as current HR can not be extrapolated that far in the future.
Please don't forget to counsel your patient for participation in the PRO-RCC national cohort!
Denne algoritme er beregnet til uddannelses-, trænings- og informationsformål. Den må ikke bruges til at støtte medicinsk beslutningstagning eller til at levere medicinske eller diagnostiske ydelser. Læs vores fulde disclaimer.
With an Evidencio Community account you can:
A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.
{{ (typeof row === 'object') ? row.label : row }} |
{{ column }} | |
---|---|
{{ row.label }} | {{ value }} |
Please enter a password
A password has to be at least 8 characters.
A password cannot be longer then 64 characters.
Choose a password with at least one capital letter.
Choose a password with at least one special character (@$!%*#?&)
Please agree to the Terms & Conditions and the Disclaimer
Please provide your e-mail address and we'll send you a link to reset your password.
Email Address
Please enter a valid email
If an account was registered with this email address you will receive a recovery link in your mail.
Please use the reset password link in it to set your new password.
Didn't receive the email yet? Please check your spam folder, or resend the email.